*Read Disclaimer Sponsored Content
{{current_date_full}} | Unsubscribe
Hello!
New Alert: Polyrizon Ltd. (NASDAQ: PLRZ)
PLRZ is our brand new NASDAQ high-growth alert.
This is a hidden gem opportunity that not many have seen and we are among the first to bring it to your attention.
The chart setup is pointing to a potential breakout opportunity and momentum can build very quickly.
PLRZ has a history of experiencing high volatility & the company announced multiple big accomplishments recently.
PLRZ is a NASDAQ listed “development-stage biotech company.”
PLRZ is “specializing in the development of innovative medical device hydrogels delivered in the form of nasal sprays, which form a thin hydrogel-based shield containment barrier in the nasal cavity that can provide a barrier against viruses and allergens from contacting the nasal epithelial tissue”.
PLRZ has “two core platform technologies: Capture and Contain (C&C™) and Trap and Target (T&T)”
The company’s “proprietary Capture and Contain TM, or C&C, hydrogel technology, comprised of a mixture of naturally occurring building blocks, is delivered in the form of nasal sprays, and potentially functions as a "biological mask" with a thin shield containment barrier in the nasal cavity”.
“The Capture and Contain (C&C™) platform utilizes a natural 3D polymeric network engineered to adhere optimally to the nasal mucosa.”
This advanced network “forms a physical barrier that captures and contains airborne biological threats, such as allergens, viruses (such as Influenza), and molds, preventing their penetration and protecting the body.”
PLRZ are further developing certain aspects of its “C&C hydrogel technology such as the bioadhesion and prolonged retention at the nasal deposition site for intranasal delivery of drugs”.
PLRZ “refers to its additional technology, which is in an earlier stage of pre-clinical development, that is focused on nasal delivery of active pharmaceutical ingredients, or APIs, as Trap and Target, or T&T.”
“The T&T platform represents a significant advancement in intranasal drug delivery, offering a novel approach to improving the bioavailability of active pharmaceutical ingredients (APIs) and addressing critical challenges in both local and systemic drug delivery.”
“Key Potential Features of the Trap & Target (T&T) Platform:
Prolonged Residence Time: Enhancing the duration that drugs remain at the nasal absorption site, facilitating better absorption and efficacy.
Improved Bioavailability: Increasing the amount of drug that reaches systemic circulation by bypassing first-pass metabolism and potentially improving therapeutic outcomes.
Controlled Release: Allows for precise management of API release kinetics to ensure optimal therapeutic levels over time.
Prevention of Dripping: The system is designed to prevent the formulation from dripping out of the nasal cavity to ensure maximum efficacy and patient comfort.
Biodegradable Components: Utilizing safe and environmentally friendly biodegradable polymers .
Versatility: Compatibility with a wide range of drug types, including small molecules, proteins, peptides, and antibodies, making it suitable for diverse therapeutic applications.”
“The T&T platform leverages the nasal cavity's rich vascularization to facilitate both local and systemic drug delivery, offering a promising solution for various therapeutic applications, such as corticosteroids for allergic rhinitis, benzodiazepines for epileptic seizures and naloxone for opioid overdose.”
“By enhancing drug absorption and bioavailability, the platform has the potential to improve the treatment of respiratory conditions, central nervous system disorders, and other medical needs.”
The company's lead product is NASARIX™, “Polyrizon's proprietary nasal spray designed to create a protective barrier within the nasal cavity, helping to prevent contact between inhaled allergens and the nasal mucosa”.
The product is being developed as a “non-drug approach for the management of seasonal allergic rhinitis”.
The company has announced multiple accomplishments recently.
In May, the company announced:
“Polyrizon Announces U.S. Patent Expansion for Its Intranasal Drug Delivery Platform”
Tomer Izraeli, CEO of Polyrizon, commented:
"The submission of amended claims in our U.S. patent application represents another important step in strengthening our intellectual property protection. We believe that expanding the scope of protection to include drug delivery systems and methods of use enhances the value and potential applicability of our platform across a broad range of therapeutic areas."
In addition, the company also announced:
“Polyrizon Advances Towards Human Clinical Trials: Secures First U.S. Clinical Site for NASARIX™ Allergy Blocker Clinical Trial”
PLRZ announced “the signing of its first Clinical Trial Agreement (CTA) with a U.S.-based clinical research site specializing in allergy studies, marking a key milestone toward the initiation of its clinical program for the NASARIXTM (PL-14) Allergy Blocker.”
“The clinical site, located in Texas, will serve as the first participating center in Polyrizon's planned multi-center study evaluating the safety, tolerability, and efficacy of the NASARIXTM Allergy Blocker in patients with seasonal allergic rhinitis.”
The clinical study, titled "Evaluation of the Efficacy, Safety, and Tolerability of PL-14 Allergy Blocker Compared to Saline Spray in Patients with Seasonal Allergic Rhinitis", will assess the performance of Polyrizon's investigational nasal spray designed to create a protective barrier against airborne allergens.
Here are some of the company’s comments from this press release:
"This agreement represents an important step in transitioning NASARIXTM from development stage into potential clinical validation," said Tomer Izraeli, CEO of Polyrizon. "We are pleased to collaborate with an experienced clinical team as we advance toward initiating our first-in-human clinical study."
In June, the company announced:
“Polyrizon Makes Strong Clinical Progress: Secures Three U.S. Sites for NASARIX™ Trial”
PLRZ announced “it has signed agreements with two additional U.S. clinical sites. This brings the total to three major contracted sites for its upcoming NASARIX™ (PL-14) clinical study.”
“These three sites represent the largest and most strategically important centers in the Company's planned multi-center clinical trial and are expected to contribute the highest rates of patient enrollment. The study will evaluate the safety, tolerability, and efficacy of the NASARIX™ Allergy Blocker in patients with seasonal allergic rhinitis.”
Here are some of the company’s comments from this press release:
"We are very encouraged by the rapid expansion of our clinical site network, particularly with the addition of two highly experienced and high-enrollment centers," said Tomer Izraeli, CEO of Polyrizon. "We believe that securing the three leading sites early positions us strongly for efficient patient recruitment and timely study execution as we prepare to initiate our multi-center clinical trial."
Plus, the company also announced:
“Polyrizon Receives Notice of European Patent Publication for Innovative Mucoadhesive Nasal Drug Delivery Technology”
As the company further explains:
“Nasal drug delivery has emerged as an increasingly attractive administration route for a wide range of therapeutic compounds, offering rapid onset of action, non-invasive administration, and the potential to bypass gastrointestinal degradation and first-pass metabolism. Polyrizon's technology is intended to address one of the key challenges of nasal administration, limited residence time within the nasal cavity, through the development of advanced mucoadhesive polymer systems.”
Importantly:
“The publication of the patent application represents a significant milestone in the Company's strategy to strengthen its intellectual property portfolio supporting future pharmaceutical applications and collaborations in the nasal drug delivery field.”
Here are some of the company’s comments:
"The forthcoming publication of this European patent application marks an important step in strengthening our position in the growing nasal drug delivery market," said Tomer Izraeli, Chief Executive Officer of Polyrizon. "We believe our proprietary mucoadhesive polymer technology has the potential to improve the performance of nasal drug delivery systems across a broad range of therapeutic applications. Expanding our patent portfolio remains a key component of our strategy as we continue to advance innovative solutions for pharmaceutical partners and future product opportunities."
Furthermore, on June 15, 2026, the company announced:
“Polyrizon Advances NASARIX™ Development with Key Human Study to Characterize Nasal Residence Time and Support FDA Regulatory Pathway”
“New performance and characterization study in collaboration with leading European medical center marks a critical milestone in the validation of the NASARIX™ allergy blocker's protective barrier function”
On June 17, the company also announced:
“Polyrizon Receives Notice of U.S. Patent Publication for Mucoadhesive Drug Delivery Platform”
“The patent application covers Polyrizon's proprietary Trap & Target™ (T&T) mucoadhesive polymer technology platform for nasal drug delivery. The technology is designed to enhance the interaction between pharmaceutical formulations and the nasal mucosa, potentially increasing formulation retention, improving drug absorption, and enabling more efficient delivery of active pharmaceutical ingredients through the nasal route.”
Furthermore:
“The published patent application describes biocompatible mucoadhesive compositions designed to form a uniform and durable film on mucosal surfaces while enabling enhanced delivery and retention of pharmaceutical actives. The technology combines sulfated polysaccharides, with hydrophilic polymers, partially crosslinked with divalent ions to create formulations with improved viscosity, sprayability, and film-forming properties.
The patent application further outlines the potential use of the platform in oral and nasal drug delivery systems, including sprays, gels, inhalation products, and formulations intended for localized and systemic administration of therapeutic agents through mucosal tissues.
According to the application, the platform may support delivery of a broad range of therapeutic compounds, including anti-inflammatory drugs, vaccines, biologics, and additional pharmaceutical actives, with the goal of improving mucosal retention and bioavailability.”
In addition:
“Polyrizon Makes Strong Progress: Receives Central IRB Approval for its Allergy Blocker Clinical Trial”
PLRZ “announced it has received central IRB approval to begin its first human clinical trial for NASARIX™, the Company's innovative nasal spray designed to block airborne allergens.”
Importantly:
“This approval from BRANY Institutional Review Board (granted June 18, 2026) is a key regulatory milestone for the Company. It confirms that the study protocol, patient consent forms, and trial materials have been reviewed and approved by the central IRB and satisfy applicable ethical and participant protection requirements.”
Here are some of the comments from this press release:
"This IRB approval represents an important milestone in the advancement of our NASARIXTM clinical development program," said Tomer Izraeli, CEO. "We are pleased to have received approval for the study master file and look forward to progressing toward site activation and patient enrollment following completion of site-specific IRB approvals."
Most recently, the company announced:
“Polyrizon Announces Successful Results for NASARIX™ Biocompatibility Program, Supporting Advancement Towards First in Human Clinical Trial”
PLRZ “announced successful results from its biocompatibility evaluation program for its proprietary NASARIXTM Allergy Blocker nasal spray, with all required biological safety tests meeting their predetermined acceptance criteria.”
“The comprehensive evaluation program was designed in accordance with internationally recognized standards for biological safety assessment of medical devices, including the ISO 10993 series, FDA guidance, and applicable European regulatory requirements. The program was developed to assess the safety and biocompatibility profile of NASARIXTM, a drug-free mucoadhesive nasal spray intended to help reduce exposure to airborne allergens associated with seasonal allergic rhinitis.
The completed testing program evaluated key biological safety endpoints identified for the device, including:
Cytotoxicity
Sensitization
Irritation / Intracutaneous Reactivity
Material-Mediated Pyrogenicity
Acute Systemic Toxicity
In addition, long-term systemic toxicity was assessed through a toxicological risk assessment conducted in accordance with ISO 10993-17, demonstrating substantial safety margins across the product's constituent materials under intended conditions of use.”
Here are some of the company’s comments from this press release:
"We are pleased to report the successful completion of the NASARIXTM biocompatibility program," said Tomer Izraeli, CEO of Polyrizon. "Achieving positive results across all required biological safety assessments represents a significant milestone in our development program and further supports the biocompatibility safety profile of NASARIXTM as we continue advancing its clinical and regulatory pathway."
We believe PLRZ could be positioned for big upside potential.
Make sure to do your own due diligence.
Happy Trading!
SmallCapStocks Team
Note: We encourage all traders and investors to develop personal trading rules that you can follow and that work for you. Always protect your downside and note that we alert extremely volatile short-term opportunities. Before investing in securities, you should always consult with your financial, tax and legal advisor and never invest money you cannot afford to lose.
DISCLAIMER:
You should read and understand this disclaimer in its entirety before joining the website or email/blog list of SmallCapStocks.com (the “Publisher”). The information (collectively the “Advertisement”) disseminated by email, text or other method by the Publisher including this publication is a paid commercial advertisement and should not be relied upon for making an investment decision or any other purpose. The Publisher is engaged in the business of marketing and advertising the securities of publicly traded companies in exchange for compensation. The track record, gains, upside, and/or losses mentioned in the Advertisement, if any, should not be considered as true or accurate or be the basis for an investment. The Publisher does not verify the accuracy or completeness of any information included in the Advertisement. While the Publisher does not charge for the SMS service, standard carrier message and data rates may apply. To unsubscribe from receiving promotional text messages to your phone sent via an autodialer, using your phone reply to the sender’s phone number with the word STOP or HELP for help.
The Advertisement is not a solicitation or recommendation to buy securities of the advertised company. An offer to buy or sell securities can be made only by a disclosure document that complies with applicable securities laws and only in the states or other jurisdictions in which the security is eligible for sale. The Advertisement is not a disclosure document. The Advertisement is only a favorable snapshot of unverified information about the advertised company. An investor considering purchasing the securities, should always do so only with the assistance of his legal, tax and investment advisors. Investors should review with his or her investment advisor, tax advisor or attorney, if and to the extent available, any information concerning a potential investment at the web sites of the U.S. Securities and Exchange Commission (the "SEC") at www.sec.gov; the Financial Industry Regulatory Authority (the "FINRA") at www.FINRA.org, and relevant State Securities Administrator website and the OTC Markets website at www.otcmarkets.com. The Publisher cautions investors to read the SEC advisory to investors concerning Internet Stock Fraud at www.sec.gov/consumer/cyberfr.htm, as well as related information published by the FINRA on how to invest carefully. Investors are responsible for verifying all information in the Advertisement. As an advertiser, we do not verify any information we publish. The Advertisement should not be considered true or complete.
The Publisher does not offer investment advice or analysis, and the Publisher further urges you to consult your own independent tax, business, financial and investment advisors concerning any investment you make in securities particularly those quoted on the OTC Markets. Investing in securities is highly speculative and carries an extremely high degree of risk. You could lose your entire investment if you invest in any company mentioned in the Advertisement. You acknowledge that we are not an investment advisory service, a broker-dealer or an investment adviser and we are not qualified to act as such. You acknowledge that you will consult with your own independent, tax, financial and/or legal advisers regarding any decisions as to any company mentioned here. We have not determined if the Advertisement is accurate, correct or truthful. The Advertisement is compiled from publicly available information, which include, but are not limited to, no cost online research, magazines, newspapers, reports filed with the SEC or information furnished by way of press releases. Because all information relied upon by us in preparing an advertisement about an issuer comes from a public source, it is not reliable, and you should not assume it is accurate or complete.
Owners and operators of the Publisher have been compensated nine thousand dollars by bank wire transfer on 7/23/26 for the distribution of this advertisement about PLRZ dated 7/27/26. The Publisher and its owners and operators hold no stocks or bonds in companies discussed in the Advertisement. Owners and operators of the Publisher own several newsletters, therefore you may receive multiple publications and emails featuring companies at different or the same time.
You are receiving this report/release because you subscribed to receive it at our website or through a third-party site. All our newsletters include an "unsubscribe" link, and you can remove yourself at any time from our newsletters by clicking on that "unsubscribe" link. You can also contact us at [email protected] to change your information at any time. By your subscription to our profiles, the viewing of this profile and/or use of our website, you have agreed and acknowledged the terms of our full disclaimer and privacy policy which can be viewed at the following link:
www.SmallCapStocks.com/Disclaimer and www.SmallCapStocks.com/Privacy-Policy
By accepting the Advertisement, you agree and acknowledge that any hyperlinks to the website of (1) a client company, (2) the party issuing or preparing the information for the company, or (3) other information contained in the Advertisement is provided only for your reference and convenience. The advertiser is not responsible for the accuracy or reliability of these external sites, nor is it responsible for the content, opinions, products or other materials on external sites or information sources. If you use, act upon or make decisions in reliance on information contained in any disseminated report/release or any hyperlink, you do so at your own risk and agree to hold us, our officers, directors, shareholders, affiliates and agents harmless. You acknowledge that you are not relying on the Publisher, and we are not liable for, any actions taken by you based on any information contained in any disseminated email or hyperlink.